NCT04702113

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics: the Lighthouse Pilot (Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Cipherome, Inc. · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of toxicity of a therapeutic regimen.

Detailed description

The Lighthouse tool incorporates pharmacogenetic (PGx) variants from well-established, evidence-based guidelines to provide personalized drug response profile(s) to guide treatment decisions. The patient specimen is genotyped using a proprietary, carefully curated pharmacogenetic variant panel to determine the individual's phenotype. The Lighthouse report (PGx findings) are provided to the clinician, and a notification is generated when the patient has a genotype with a deleterious drug-metabolizing phenotype. Evaluating the South Texas community for the pilot project will enhance the understanding of the impact of genetic variants on individuals of Hispanic/Latino ancestry, especially as the variants pertain to the efficacy and safety of medications.

Conditions

• Thrombosis
• Stent Thrombosis
• Bleeding
• Myocardial Infarction
• Ischemic Stroke

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Cipherome Lighthouse Pilot	Preemptive pharmacogenomic testing

Timeline

• Start date: 2020-12-03
• Primary completion: 2023-07-26
• Completion: 2023-07-27
• First posted: 2021-01-08
• Last updated: 2023-09-29

Locations

1 site across 1 country: United States